Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InsmedINSM +3.45%69 Market Cap is $28,215 Mil as of Sep. 09, 2026. GuruFocus rates INSM with a GF Score™ of 69/100 and a GF Value™ of $210.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,421 Biotechnology companies, Insmed ranks better than 99.09% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Insmed's share price for the quarter that ended in Jun. 2026 was $106.62. Insmed's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 218 Mil. Therefore, Insmed's market cap for the quarter that ended in Jun. 2026 was $23,273 Mil.
Insmed's quarterly market cap
declined
from Dec. 2025 ($37,289 Mil) to Mar. 2026 ($35,406 Mil) and
declined
from Mar. 2026 ($35,406 Mil) to Jun. 2026 ($23,273 Mil).
Insmed's annual market cap
increased
from Dec. 2023 ($4,586 Mil) to Dec. 2024 ($12,385 Mil) and
increased
from Dec. 2024 ($12,385 Mil) to Dec. 2025 ($37,289 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Insmed's Enterprise Value for Today is $27,634 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Insmed Market Cap Related Terms
Insmed Market Cap Historical Data
* Premium members only.
The historical data trend for Insmed's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Insmed's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's Market Cap distribution charts can be found below:
* The bar in red indicates where Insmed's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Insmed's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (INSM) has a Market Cap of $28,215 Mil as of Sep. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Insmed and its competitors. According to the industry distribution chart, Insmed ranks #13 out of 1421 companies in the Biotechnology industry, placing it in the top 0.90000000000001%.
Is Insmed's Market Cap too high?
Insmed's current Market Cap is $28,215 Mil. The Biotechnology industry median Market Cap is 121.78. Insmed's value of $28,215 Mil is 23069.8% above this industry median. Based on the distribution chart, Insmed ranks #13 out of 1421 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Insmed has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Market Cap compare to BNTX and INCY?
According to the Biotechnology industry distribution chart, Insmed ranks #13 out of 1421 companies for Market Cap. This places Insmed in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.78. Insmed's value of $28,215 Mil is 23069.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.78, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insmed's current Market Cap of $28,215 Mil is 23069.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Insmed and its competitors. For the Biotechnology industry, the median Market Cap is 121.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insmed's current Market Cap is $28,215 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (INSM) is currently considered Possible Value Trap. The stock's GF Value™ is $210.23, compared to a current price of $129.20 — trading 38.5% below its estimated fair value. The current Market Cap is $28,215 Mil and 23069.8% above the Biotechnology industry median of 121.78. Insmed's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Insmed (INSM), the current Market Cap is $28,215 Mil as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of $129.20 is trading 38.5% below its estimated GF Value™ of $210.23.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for INSM:
Market Cap: $28,215 Mil
GF Value™: $210.23 vs. price of $129.20 (38.5% below fair value)
Industry Position: 23069.8% above the Biotechnology median (#13 of 1421)
No single metric tells the full story. See the INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
69GF Score
Get the complete analysis for INSM
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INSM has been successfully added to your 
